A study to evaluate the effect of ultrasound treatment on nodules in multiple sclerosis patients

What Was Tested

This randomized controlled trial paper looks at Glatiramer Acetate in the context of multiple sclerosis.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Twenty-two multiple sclerosis patients were enrolled during 2013 and randomized to two groups: in the control group patients were treated only with a conventional gel prescribed for cellulite and nodules, while in the experimental group the gel was combined with ultrasound therapy.

Patients were treated during 10 weeks and followed up for 10 additional weeks.

How the Study Was Run

The researchers set it up as a randomized and pilot study.

Because people in this Glatiramer Acetate study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

It is described as a pilot, a small early test of whether a larger Glatiramer Acetate study would be practical.

The timeline in the abstract includes 10 weeks.

Three nodules were assessed for each patient, measuring size, pain and redness at 0, 10 and 20 weeks.

What Was Measured

PubMed files the paper under topics including Antineoplastic Agents, Glatiramer Acetate, Immunosuppressive Agents, Interferons, Linear Models, Multiple Sclerosis and Outcome Assessment, Health Care.

The authors tagged it with the keywords first-line treatment, nodule, skin reaction and therapeutic ultrasound.

What This Means in Plain Language

The paper is a randomized and pilot study of Glatiramer Acetate in people with multiple sclerosis over 10 weeks.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (The International journal of neuroscience), a journal based in England.

More context: the Glatiramer Acetate compound page, Multiple sclerosis research.